Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,033 |
Reported balance
After 2026-10-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 45,838 · Balance 47,033 F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 95,265 |
Reported balance
After 2026-10-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-10-06 · Grant · Acquired 48,232 · Balance 95,265 F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| Common StockSEC Table I · non-derivative | Direct | 24,039 |
Reported balance
After 2026-10-06 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2026-10-06 · Tax withholding · Disposed 71,226 · Balance 24,039 F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2026-10-06 · Disposition to issuer · Disposed 69,979 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
F2: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F3: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).
F4: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 9, 2026 01:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Disposition to issuerCommon Stock | 69,979 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418304 · ownership.xml · nonDerivative · entry 4 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 71,226 | $38.61 | $2,750,035.86 |
DisclosureSEC source: 0001193125-26-418304 · ownership.xml · nonDerivative · entry 3 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,039 F4 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award. Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 48,232 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418304 · ownership.xml · nonDerivative · entry 2 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,265 F3 · price: The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| October 06, 2026 Filed Oct 9, 2026 01:54 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 45,838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418304 · ownership.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,033 F2 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). Read SEC document |
| September 18, 2026 Filed Sep 22, 2026 21:11 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 421 | $36.69 | $15,446.49 |
DisclosureSEC source: 0001628280-26-063077 · wk-form4_1790111504.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,135 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 22:47 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 275 | $29.15 | $8,016.25 |
DisclosureSEC source: 0001628280-26-049086 · wk-form4_1784674056.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,556 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:50 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 420 | $26.04 | $10,936.80 |
DisclosureSEC source: 0001628280-26-044698 · wk-form4_1782161424.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,831 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 19, 2026 Filed Mar 23, 2026 21:08 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Tax withholdingCommon Stock | 1,681 | $19.12 | $32,140.72 |
DisclosureSEC source: 0001628280-26-020579 · wk-form4_1774300132.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,251 F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 22:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 111 | $20.74 | $2,302.14 |
DisclosureSEC source: 0001628280-26-015342 · wk-form4_1772748632.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,932 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 24,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012471 · wk-form4_1772146521.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,043 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 22:35 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 110 | $26.74 | $2,941.40 |
DisclosureSEC source: 0001628280-25-054279 · wk-form4_1764369314.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,927 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 275 | $27.82 | $7,650.50 |
DisclosureSEC source: 0001628280-25-045913 · wk-form4_1761166957.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,037 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 07-17-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| September 11, 2025 Filed Sep 15, 2025 21:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 72 | $26.83 | $1,931.76 |
DisclosureSEC source: 0002047541-25-000003 · wk-form4_1757970111.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,312 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 09-01-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 111 | $25.44 | $2,823.84 |
DisclosureSEC source: 0001628280-25-041302 · wk-form4_1756415234.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,384 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 21:33 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,115 | $21.22 | $23,660.30 |
DisclosureSEC source: 0001628280-25-035591 · wk-form4_1753220003.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,495 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 07-17-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:24 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 65 | $23.70 | $1,540.50 |
DisclosureSEC source: 0001628280-25-031100 · wk-form4_1749763442.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,610 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 09-01-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| May 28, 2025 Filed May 30, 2025 21:57 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 109 | $22.46 | $2,448.14 |
DisclosureSEC source: 0001628280-25-028695 · wk-form4_1748642210.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,675 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 22,919 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014180 · wk-form4_1742512051.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,784 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 22:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 88 | $24.03 | $2,114.64 |
DisclosureSEC source: 0001628280-25-010568 · wk-form4_1741212833.xml · nonDerivative · entry 2 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,865 F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 09-01-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 136 | $25.46 | $3,462.56 |
DisclosureSEC source: 0001628280-25-010568 · wk-form4_1741212833.xml · nonDerivative · entry 1 Werner Sean · CIK 0002047541 · Chief Technology Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,953 F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.